Aureka Raises $100M for Bio Models
Aureka Biotechnologies raised a $100M Series B for biological foundation models aimed at drug discovery.
AI biology is moving from software support into the core scientific engine of new biotech companies.
What happened
Aureka Biotechnologies raised a $100M Series B. The company is developing biological foundation models for drug discovery, aiming to use AI systems to understand and design around complex biological data.
The round gives Aureka more capital to build in a market where the cost and uncertainty of drug discovery remain extremely high.
Why it matters
Drug discovery is one of the most attractive but hardest targets for AI. Better models could help identify targets, predict biological behaviour, design molecules or narrow down experiments faster.
The investor signal is that AI-native biotech platforms are still getting funded when they can connect model development to credible scientific workflows.
The bigger picture
The strongest AI-biotech companies are not just adding chat interfaces to lab work. They are trying to make biology itself more model-driven.
Aureka’s round fits that shift: investors are backing platforms that could become the infrastructure layer for faster, cheaper and more targeted therapeutic discovery.